Letters Sitagliptin in patients with type 2 diabetes

Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3568 (Published 04 June 2013) Cite this as: BMJ 2013;346:f3568
  1. Jose Mario Franco de Oliveira, associate professor of medicine1
  1. 1Universidade Federal Fluminense, Rio de Janeiro, RJ 22230-001, Brazil
  1. jmariofranco{at}gmail.com

I have several questions arising from the study by Eurich and colleagues on the safety and effectiveness of sitagliptin in patients with type 2 diabetes.1

Firstly, is an observational study qualified to suggest a “safety” message when the patients were followed-up for a mean of only 2.5 years,1 whereas most patients have to live …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial